Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6778426 | 0.83 | KMT2A (0.48) | HTTKCNA5KMT2AGPBAR1ALDH1A1 | |
| SCHEMBL6780637 | 0.83 | LMNA (0.46) | HTTKCNA5KMT2ALMNAPDCD1 | |
| SCHEMBL6780567 | 0.82 | GPBAR1 (0.49) | HTTKCNA5KMT2AGPBAR1POLB | |
| SCHEMBL6777732 | 0.81 | LPAR1 (0.52) | HTTKCNA5KMT2APOLBALDH1A1 | |
| SCHEMBL6774110 | 0.80 | SGMS2 (0.50) | HTTKCNA5KMT2APOLBPDCD1 | |
| SCHEMBL6780767 | 0.79 | ALDH1A1 (0.46) | HTTKCNA5KMT2AGPBAR1THRB | |
| SCHEMBL7673590 | 0.78 | ALDH1A1 (0.46) | HTTKCNA5KMT2AGPBAR1ALDH1A1 | |
| SCHEMBL10686818 | 0.77 | HTT (0.60) | HTTKCNA5KMT2ATHRBPOLB | |
| SCHEMBL6774316 | 0.77 | ALDH1A1 (0.51) | HTTKMT2ALMNAALDH1A1MAPT | |
| SCHEMBL6779730 | 0.77 | GPBAR1 (0.44) | HTTKCNA5KMT2AGPBAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6780883-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS | WARNER-LAMBERT COMPANY | 2004-08-24 | — | — | US | claimed |
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | BOOTH RICHARD JOHN (US) | 2002-10-24 | — | — | US | claimed |
| US-6780883-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS | WARNER-LAMBERT COMPANY | 2004-08-24 | — | — | US | disclosed |
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | BOOTH RICHARD JOHN (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | CETP, MTTP, LCAT | HTT 2758/4885KCNA5 3796/4885KMT2A 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.